Bachem renews supply contract with AstraZeneca

February 07, 2017

Bubendorf/Basel, 7 February 2017 – The Bachem Group (SIX: BANB) announced today the renewal of its supply agreement with AstraZeneca for the peptide active substance Goserelin. The extended partnership enhances the successful cooperation between both companies. Under the terms of the agreement, AstraZeneca will continue acquiring the peptide active substance Goserelin from Bachem for the next five years. Bachem has been supplying AstraZeneca with Goserelin for more than 25 years.


At Bachem, we believe that our employees make the difference. Representing our corporate culture of passion and commitment, they are the foundation of our success. We therefore strive to attract, retain, and develop highly motivated, well-qualified individuals.

View all jobs

Click here >>

Contact us


  • Please choose if you would like to receive additional email communications from Bachem:

  • Fields marked with an asterisk (*) are required

  • Hidden
  • Hidden
  • This field is for validation purposes and should be left unchanged.